Preclinical studies have shown that ATR is activated following cisplatin treatment and that ATR inhibition can profoundly sensitise tumour cells, including oesophageal cancer cells to platinum-based chemotherapy and radiotherapy [14–17]. This evidence concerns the gene ATR and carcinoma of esophagus.